Introduction
============

The tyrosine kinase c-Abl has been shown to co-localize with tangles, plaques, and granulovacuolar degeneration in Alzheimer's disease (AD) \[[@B1]\]. The c-Abl kinase also phosphorylates tau, the amyloid precursor protein (APP) and Fe65, an adaptor protein thought to play a role in APP processing \[[@B2]-[@B6]\]. The c-Abl tyrosine kinase has been shown to be activated by oxidative stress and treatment with Aβ peptides in neurons in culture \[[@B7]\]. These known activators of c-Abl are associated with aging and AD and, together with data showing c-Abl activation and co-localization with the characteristic lesions of AD, suggest that c-Abl may be activated during aging and neurodegenerative disease. The AblPP/tTA mouse model, which expresses an inducible, constitutively active form of c-Abl under the CamKIIα promoter using the Tet-Off system, was created to investigate the effects of c-Abl expression in adult forebrain neurons. The AblPP/tTA mouse develops progressive neurodegeneration and neuroinflammation in the CA1 region of the hippocampus, indicating that activation of c-Abl alone in adult neurons is sufficient to cause neuronal loss and inflammation \[[@B8]\].

Aberrant cell cycle activation has been shown to occur in neurons in human AD prior to neuronal death \[[@B9]-[@B13]\], and cell cycle events have been shown to precede amyloid deposition and microglial activation in several mouse models of AD \[[@B14]\]. Additionally, mice expressing a transgene that forces postmitotic neurons into the cell cycle recapitulate all the major pathological hallmarks of AD -- neurodegeneration, neurofibrillary tangles, and amyloid plaques \[[@B15]\]. Chronic neuroinflammation and upregulation of a multitude of cytokines has been shown to occur in AD \[[@B16]-[@B26]\]. Others have suggested that stress/death signals produced by neurons may be the impetus for chronic inflammation in the brain \[[@B19],[@B27]\].

Previously, the pathways that might be induced by c-Abl activity in neurons were unknown. In an effort to elucidate these pathways, we performed gene expression analysis on the forebrains of young AblPP/tTA mice at 2 or 4 weeks offf doxycycline. The expression of thousands of genes was altered in the AblPP/tTA mouse brain, and we chose to focus on two of the top pathways found to be upregulated in the AblPP/tTA mouse: cell cycle and interferon signaling. We show the anatomic location of the induction of cell cycle and interferon stimulated genes in the AblPP/tTA mouse brain, and that changes in interferon-stimulated gene expression occurred in neurons and co-localized in the CA1 region of the hippocampus, which was previously shown to develop severe neuronal loss and neuroinflammation. These data suggest that c-Abl expression in neurons can stimulate interferon signaling in the brain, and that this pathway may play a role in stimulating gliosis and promoting neuronal loss.

Materials and methods
=====================

Mice
----

Cohorts of five to six AblPP/tTA mice \[[@B8]\] and five to six wild-type littermates were used. Additional control mice carried either the CamKII-tTA gene alone or the c-Abl transgene alone. There was no elevation of c-Abl activity in these single transgenic mice. All mice were kept on a diet containing 200 mg/kg doxycycline (Bio-Serv Frenchtown, NJ 08825) throughout breeding, pregnancy, and weaning. Animals were housed in a facility with a 12-hour light/dark cycle and were provided with free access to water and food at all times. Mice were taken off doxycycline at approximately 4 weeks of age in order to induce c-Abl expression. Mice were euthanized with isofluorane and decapitated. Brains were hemisected sagitally. For all experiments, one half of the forebrain (randomly selected) was homogenized and frozen, while the other half was used for microarray analysis, quantitative reverse transcription PCR (qPCR), or immunohistochemistry.

Gene expression analysis
------------------------

Cohorts of six AblPP/tTA, six wild-type littermates, six c-Abl, and six CamKII-tTA mice at 2 or 4 weeks off doxycycline were used for gene expression analysis. The forebrain of one hemisphere was dissected away from hindbrain and frozen at −80°C prior to RNA extraction. Total RNA from mouse brain was extracted using standard protocols \[[@B28]\]. Total RNA was extracted with an RNeasy kit Valencia, CA 91355 , and RNA was measured for quality using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Reverse transcription was performed using an ArrayScriptTM reverse transcriptase and T7-Oligo (dT)24 primers, followed by second-strand synthesis to generate double-stranded cDNA. The cDNA was converted to biotin-labeled cRNA (TotalprepTM RNA Labeling Kit, Ambion), then hybridized to the microarray platform. Mouse WG-6 Expression BeadChip (Illumina, San Diego, CA, USA) with 45,281 probes was the microarray platform used. Microarrays were utilized according to the manufacturer's guidelines (Illumina).

Data was analyzed using the BeadStudio software (Illumina) and BRB Array Tools 3.8, a statistical software package designed for microarray analysis developed by the National Institutes of Health (linus.nci.nih.gov/BRB-ArrayTools.html). Expression differences were considered statistically significant if their *P* values were less than 0.001 using an F-test. Ingenuity Pathways Analysis application was used to determine which biological pathways were most upregulated in the AblPP/tTA mouse based on statistically significant changes in gene expression. The online database Interferome \[[@B29]\] was used to identify interferon signaling genes.

Quantitative PCR
----------------

qPCR was performed according to standard protocols \[[@B30]\]. Briefly, total RNA extraction was performed using TRIzol reagent (Invitrogen) on hippocampus or cortex of cohorts of five AblPP/tTA mice and five wild-type controls at 2 weeks off doxycyline and 4 weeks off doxycycline according to manufacturer's instructions. RNA was measured for quality using a NanoDrop. A SYBRGreen PCR mix was used to conduct qPCR with the ABI Prism 7900HT (Applied Biosystems). β-actin was used as an internal control, and each assay was performed in triplicate. Primers used for qPCR are listed in Table [1](#T1){ref-type="table"}. The median value of the replicates for each sample was calculated and expressed as the cycle threshold (C~*T*~). ΔC~*T*~ was calculated as C~*T*~ of β-actin minus the C~*T*~ of the gene of interest in each sample. The relative amount of target gene expression in each sample was calculated as 2^ΔC*T*^, and fold change was calculated by dividing 2^ΔC*T*^ of the gene of interest by 2^ΔC*T*^ of the gene in the control sample.

###### 

Antibodies (IHC = immunohistochemistry, IHC-P = immunohistochemistry, paraffin sections; WB = immunoblot)

      **Epitope**       **Antibody**   **Application**          **Source**
  -------------------- -------------- ----------------- ---------------------------
          BrdU            1170376       IHC-P, 1:400               Roche
       Cyclin B1            4135         WB, 1:1000      Cell Signaling Technology
       Cyclin D1            2926         WB, 1:1000      Cell Signaling Technology
          Cdk4              2906         WB, 1:1000      Cell Signaling Technology
          Cdk2              2546         WB, 1:1000      Cell Signaling Technology
   Polo-like kinase 1      05-844        WB, 1:1000              Millipore
         Stat1             9172S         WB, 1:1000      Cell Signaling Technology
       IHC, 1:500                                       
      Stat1 pY701          9167S         WB, 1:1000      Cell Signaling Technology
       IHC, 1:250                                       
      Stat1 pS727          9177 s        WB, 1:1000      Cell Signaling Technology

BrdU, bromodeoxyuridine.

Antibodies
----------

Antibodies used for immunoblotting and immunohistochemistry are listed in Table [2](#T2){ref-type="table"}.

###### 

Primers

           **Gene**               **Primer sequences**       **Source**
  --------------------------- ---------------------------- --------------
             IFNα              F: GGATGTGACCTTCCTCAGACTC      OriGene
   R: ACCTTCTCCTGCGGGAATCCAA                               
             IFNβ               F: CAGCTCCAAGAAAGGACGAAC    qPrimerDepot
   R: GGCAGTGTAACTCTTCTGCAT                                
             IFNγ               F: GCGGCCTAGCTCTGAGACAA       Primer3
    R: GACTGTGCCGTGGCAGTAAC                                
             IL-6              F : ATGGATGCTACCAAACTGGAT     RTPrimerDB
   R : TGAAGGACTCTGGCTTTGTCT                               
             IP10               F : TCCTTGTCCTCCCTAGCTCA     RTPrimerDB
   R : ATAACCCCTTGGGAAGATGG                                
             IFIT3             F: GCTCAGGCTTACGTTGACAAGG      OriGene
   R: CTTTAGGCGTGTCCATCCTTCC                               
             IRF1              F: TCCAAGTCCAGCCGAGACACTA      OriGene
   R: ACTGCTGTGGTCATCAGGTAGG                               
             Isg15             F: CATCCTGGTGAGGAACGAAAGG      OriGene
   R: CTCAGCCAGAACTGGTCTTCGT                               
             PSMB8             F: CCTTACCTGCTTGGCACCATGT      OriGene
   R: TTGGATGCTGCAGACACGGAGA                               
             Stat1             F: GCCTCTCATTGTCACCGAAGAAC     OriGene
   R: TGGCTGACGTTGGAGATCACCA                               
            β-actin              F: TGCACCACCAACTGCTTAG       Primer3
                                 R: GGATGCAGGGATGATGTTC           

Western blotting
----------------

Forebrain homogenates of AblPP/tTA mice and wild-type controls were used. Forebrain samples were homogenized in homogenization buffer (TBS with 10 mM NaF, 1 mM Na~3~VO~4~, 2 mM EGTA) with complete Mini protease inhibitors (Roche), frozen at −80°C, thawed, and spun at 14,000 rpm for 10 minutes at 4°C. Supernatants were analyzed in all experiments by immunoblotting using SDS-PAGE, according to standard protocols. Protein concentrations were normalized prior to use and all western blots were normalized to β-actin loading controls.

Bromodeoxyuridine labeling
--------------------------

Bromodeoxyuridine (BrdU), 0.5 mg/ml, was administered to cohorts of three AblPP/tTA mice and three wild-type controls in drinking water for 5 days. Mice were euthanized immediately or allowed to age for 4 weeks. For detection of BrdU incorporation, one hemisphere of the brain was fixed overnight in 4% paraformaldehyde, embedded in paraffin, and sectioned in 5 μm increments. After rehydration, sections were steamed in 10 mM citrate buffer for 20 minutes. Endogenous peroxidase activity was blocked with 3% H~2~O~2~ for 10 minutes at room temperature. Sections were then treated with 3 N HCl for 30 minutes at room temperature and blocked in 5% goat serum/2% BSA for 1 hour. Primary antibody (anti-BrdU; Roche) was diluted in blocking solution and sections were incubated overnight at 4°C. Biotinylated secondary antibody was applied for 2 hours at room temperature, followed by streptavidin-HRP for 1 hour at room temperature. A solution of 20% Superblock (ThermoScientific) in TBS + 0.05% Triton X100 was used as a diluent for the secondary antibody and streptavidin-HRP. Staining was visualized with diaminobenzidine.

Immunohistochemistry
--------------------

Hemisected brains were fixed overnight in 4% paraformaldehyde and cut sagitally into 50 μm sections using a vibratome. Standard immunohistochemistry protocols were used. Endogenous peroxidase was blocked using 3% H~2~O~2~ in 0.25% TritonX 100 in TBS for 30 minutes at room temperature. Five percent milk/TBS was used as a blocking agent and primary antibody diluent. Sections were blocked for 1 hour at room temperature and incubated in primary antibody at 4°C overnight. After washing, biotinylated secondary antibody was applied for 2 hours at room temperature. Washes were repeated, and sections were incubated with Streptavidin-HRP for 1 hour at room temperature. A solution of 20% Superblock (Thermoscientific, Rockford, IL 61101) in TBS + 0.05% Triton X100 was used as a diluent for the secondary antibody and streptavidin-HRP. Staining was visualized with diaminobenzidine.

Immunofluorescence
------------------

Endogenous peroxidase activity in vibratome sections of AblPP/tTA and wild-type control mouse brains was blocked by 3% H~2~O~2~ in 0.25% TritonX 100 in TBS for 30 minutes at room temperature. Blocking solution and primary antibody diluent was 5% milk. Sections were blocked for 1 hour at room temperature and incubated in primary antibodies at 4°C overnight. Biotinylated or fluorescently conjugated secondary antibody in 20% Superblock (ThermoScientific) in TBS + 0.05% TritonX100 was applied for 2 hours at room temperature. Sections were washed and incubated in Alexafluor conjugated streptavidin for 1 hour at room temperature and mounted on microscope slides. Secondary antibodies and streptavidin-HRP were diluted in 20% Superblock (ThermoScientific) in TBS + 0.05% TritonX100. Sections were incubated in 0.3% Sudan Black in 70% EtOH for 10 minutes at room temperature. Finally, slides were cover-slipped using Prolong® Gold anti-fade reagent with DAPI (Invitrogen). A Leica SP2 Scanning Laser Confocal Microscope was used to visualize fluorescence.

Results
=======

Identification of two pathways induced by c-Abl activation in mouse forebrain
-----------------------------------------------------------------------------

More than 6,000 genes were found to have significant changes in expression in the AblPP/tTA mice at 2 weeks off doxycyline versus wild-type controls, and more than 2,000 genes were found to have significant changes in expression in AblPP/tTA mice at 4 weeks off doxycyline. We used Ingenuity Pathways Analysis to determine the top pathways upregulated in AblPP/tTA mice versus wild-type mice at 2 and 4 weeks off doxycyline. Two of the top pathways that were shown to be upregulated in forebrains of AblPP/tTA mice were cell cycle and interferon signaling.

Cell cycle activation in the AblPP/tTA mouse
--------------------------------------------

Genes in the cell cycle pathway were strongly upregulated in AblPP/tTA mouse forebrain at 2 weeks off doxycyline, but no significant upregulation was present for any of the cell cycle-related genes at 4 weeks off doxycyline. Fold-change values of cell cycle genes in AblPP/tTA mice at 2 weeks off doxycycline are listed in Table [3](#T3){ref-type="table"}. On immunoblot analysis, increases in polo-like kinase 1 (PLK-1), cyclin B1, and CDK 4 protein levels in forebrain homogenates at 2 weeks off doxycyline are apparent; however, levels of CDK 4 and cyclin B1 decrease at 4 weeks off doxycyline (Figure [1](#F1){ref-type="fig"}). Increases in PLK1 were evident on immunoblots at 4 weeks off doxicycline, but mRNA levels were not significantly elevated at this time point, as stated above. No changes in cyclin D1 or CDK 2 protein levels were observed (data not shown). Because immunoblot analysis could only be performed on whole forebrain homogenate, BrdU incorporation studies were undertaken in order to pinpoint which anatomical regions of the forebrain were experiencing cell cycle activation. Transgenic mice and controls were separated into three groups. Cohort A was administered BrdU for 5 days prior to euthanization at 2 weeks off doxycyline, cohort B was administered BrdU for 5 days prior to euthanization at 4 weeks off doxycyline, and cohort C was administered BrdU for 5 days at the same time off doxycyline as cohort A (beginning at about 1 week off doxycyline until 2 weeks off doxycyline) but allowed to age to 6 weeks off doxycyline. Surprisingly, no animals exhibited BrdU incorporation in the CA1 region of the hippocampus, where obvious neuronal loss occurs in AblPP/tTA mice. However, extensive labeling of the olfactory bulb occurred in mice in cohort A, with somewhat less labeling in cohort B, and the least amount of labeling occurred in cohort C (Figure [2](#F2){ref-type="fig"}). These results indicated that DNA replication, indicating cell cycle activation, is a very early and transient event in AblPP/tTA mice and seems to be limited to the olfactory bulb. The lack of BrdU labeling in cohort C indicates that the cells that undergo DNA replication in the early stages of c-Abl activation are lost with time. However, there does not appear to be an increase in DNA replication or expression of cell cycle proteins in pyramidal neurons in the CA1, as no cells in this region were found to be positive for BrdU, indicating that a separate process may be at work in that population of neurons.

###### 

Cell cycle-related genes induced in AblPP/tTA mice at 2 weeks off doxycycline

   **Fold-change**   **Unique ID**   **GeneBank Accession**   **Gene symbol**                                **Description**
  ----------------- --------------- ------------------------ ----------------- ----------------------------------------------------------------------------
        5.13            7200044            NM_007631               Ccnd1                          Mus musculus cyclin D1 (Ccnd1), mRNA.
        5.04            5690441            NM_007631               Ccnd1                          Mus musculus cyclin D1 (Ccnd1), mRNA.
        4.34             20364             NM_007631               Ccnd1                          Mus musculus cyclin D1 (Ccnd1), mRNA.
        4.03            670739             NM_175659             Hist1h2ah               Mus musculus histone cluster 1, H2ah (Hist1h2ah), mRNA.
        4.03            3130609            NM_178183             Hist1h2ak               Mus musculus histone cluster 1, H2ak (Hist1h2ak), mRNA.
        3.85            3520717            NM_178188             Hist1h2ad               Mus musculus histone cluster 1, H2ad (Hist1h2ad), mRNA.
        3.85            1470341            NM_175659             Hist1h2ah               Mus musculus histone cluster 1, H2ah (Hist1h2ah), mRNA.
        3.59            5490193            NM_178182             Hist1h2ai               Mus musculus histone cluster 1, H2ai (Hist1h2ai), mRNA.
        3.58            4250711            NM_175661             Hist1h2af               Mus musculus histone cluster 1, H2af (Hist1h2af), mRNA.
        3.46            6510253            NM_178185             Hist1h2ao               Mus musculus histone cluster 1, H2ao (Hist1h2ao), mRNA.
        3.28            7200519            NM_007681               Cenpa                     Mus musculus centromere protein A (Cenpa), mRNA.
        3.27            7160253            NM_178188             Hist1h2ad               Mus musculus histone cluster 1, H2ad (Hist1h2ad), mRNA.
         3.1            4610129            NM_178184             Hist1h2an               Mus musculus histone cluster 1, H2an (Hist1h2an), mRNA.
        2.94            1580088            NM_009829               Ccnd2                          Mus musculus cyclin D2 (Ccnd2), mRNA.
         2.9            1260324            NM_009829               Ccnd2                          Mus musculus cyclin D2 (Ccnd2), mRNA.
        2.77            6060379            NM_007659               Cdc2a          Mus musculus cell division cycle 2 homolog A (S. pombe) (Cdc2a), mRNA.
        2.77            1050170            NM_013538               Cdca3               Mus musculus cell division cycle associated 3 (Cdca3), mRNA.
        2.76            4610722            NM_023223               Cdc20        Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
        2.61            6450634            NM_026560               Cdca8               Mus musculus cell division cycle associated 8 (Cdca8), mRNA.
        2.52            2190164            NM_172301               Ccnb1                          Mus musculus cyclin B1 (Ccnb1), mRNA.
        2.51            4250403            NM_011623               Top2a                 Mus musculus topoisomerase (DNA) II alpha (Top2a), mRNA.
        2.41            4390228            NM_023223               Cdc20        Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
        2.34            630446             NM_183417               Cdk2         Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
        2.33            520427             NM_011121               Plk1                 Mus musculus polo-like kinase 1 (Drosophila) (Plk1), mRNA.
        2.15            4570088            NM_023223               Cdc20        Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
        2.12            1110390            NM_178182             Hist1h2ai               Mus musculus histone cluster 1, H2ai (Hist1h2ai), mRNA.
        2.09            5820653            NM_175661             Hist1h2af               Mus musculus histone cluster 1, H2af (Hist1h2af), mRNA.
        2.05             70546             NM_178186             Hist1h2ag               Mus musculus histone cluster 1, H2ag (Hist1h2ag), mRNA.
        2.01            7550156            NM_172301               Ccnb1                          Mus musculus cyclin B1 (Ccnb1), mRNA.
        2.01            6860463            NM_009870               Cdk4                    Mus musculus cyclin-dependent kinase 4 (Cdk4), mRNA.
        1.77            1740039            NM_016756               Cdk2         Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
        1.69            610717             NM_007632               Ccnd3               Mus musculus cyclin D3 (Ccnd3), transcript variant 1, mRNA.
        1.61            1820274            NM_175384               Cdca2               Mus musculus cell division cycle associated 2 (Cdca2), mRNA.
         1.6            1500446            NM_026560               Cdca8               Mus musculus cell division cycle associated 8 (Cdca8), mRNA.
        1.58            4920148            NM_013538               Cdca3               Mus musculus cell division cycle associated 3 (Cdca3), mRNA.
        1.46            6770286             AK077367               Ccnd2                          Mus musculus cyclin D2 (Ccnd2), mRNA.
         1.4            770162             NM_177733               E2f2                   Mus musculus E2F transcription factor 2 (E2f2), mRNA.
        1.37            1570754            NM_023223               Cdc20        Mus musculus cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA.
        1.33            6550164            NM_177733               E2f2                   Mus musculus E2F transcription factor 2 (E2f2), mRNA.
        1.28            2000440            NM_183417               Cdk2         Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.
        1.26            4920468            NM_028023               Cdca4               Mus musculus cell division cycle associated 4 (Cdca4), mRNA.
        1.24            7160066            NM_028023               Cdca4               Mus musculus cell division cycle associated 4 (Cdca4), mRNA.
        1.23            3870112            NM_183417               Cdk2         Mus musculus cyclin-dependent kinase 2 (Cdk2), transcript variant 1, mRNA.

![**Cell cycle activation in the AblPP/tTA mouse.** Western blotting of wild-type versus AblPP/tTA mouse forebrain homogenates. Cyclin B1 and Cdk4 levels are elevated in mice expressing consitutively active c-Abl for 2 weeks, but not 4 weeks, consistent with increased mRNA levels (Table [3](#T3){ref-type="table"}). Polo-like kinase (PLK1) levels were elevated at 2 and 4 weeks, but mRNA levels were only elevated at 2 weeks.](1742-2094-9-208-1){#F1}

![**Cell cycle activation occurs in the olfactory bulb but not in the CA1 region of the hippocampus in AblPP/tTA mice and decreases with time.** Bromodeoxyuridine (BrdU) labeling of wild-type versus AblPP/tTA mice. Cohort A = BrdU labeling at 2 weeks, euthanized at 2 weeks; Cohort B = BrdU labeling at 4 weeks, euthanized at 4 weeks; Cohort C = BrdU labeling at 2 weeks, euthanized at 6 weeks. Scalebars: Dentate, Olfactory bulb = 400 μm, CA1 = 800 μm.](1742-2094-9-208-2){#F2}

Interferon signaling pathways in the AblPP/tTA mouse
----------------------------------------------------

Expression of interferon signaling genes was strongly upregulated in AblPP/tTA mouse forebrain at both 2 and 4 weeks off doxycyline. Table [4](#T4){ref-type="table"} lists fold change values for interferon signaling genes in AblPP/tTA mice. Interestingly, despite the strong induction of genes downstream of interferons α, β, and γ, there were no significant changes in gene expression of interferons themselves. In order to confirm these results, we selected six genes in the interferon signaling pathway and performed qPCR on the hippocampus and cortex of AblPP/tTA mice 2 and 4 weeks off doxycycline. The qPCR analysis revealed that there was strong upregulation of the six genes that were downstream of the interferons, but no significant upregulation of interferons themselves (Figure [3](#F3){ref-type="fig"}). IP10, IFIT3, IRF1, Isg15, PSMB8, and STAT1 were all significantly upregulated in AblPP/tTA mouse cortex at 4 weeks off doxycyline, and all these genes except IP10 were also significantly upregulated in the hippocampus. Despite the lack of statistical significance, IP10 does trend toward increased levels in the hippocampus at 4 weeks off doxycycline. The qPCR data indicate that the induction of interferon stimulated genes increases with time off doxycyline.

###### 

Interferon related genes increased at 2 and 4 weeks off doxicycline

   **Fold Change**   **Unique ID**   **GeneBank Accession**   **Gene symbol**   **Description**  
  ----------------- --------------- ------------------------ ----------------- ----------------- ----------------------------------------------------------------------------------------------------------------------
        9.25             9.29                460221            XM_001472500          Isg15                          PREDICTED: Mus musculus hypothetical protein LOC100038882 (LOC100038882), mRNA.
        6.23             3.27                160463              NM_010708         Lgals3bp                      Mus musculus lectin, galactoside-binding, soluble, 3 binding protein (Lgals3bp), mRNA.
        5.59             2.19               3840292              NM_010509          Ifitm3                              Mus musculus interferon induced transmembrane protein 3 (Ifitm3), mRNA.
        5.07               3                2570095              NM_010724           Psmb8        Mus musculus proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7) (Psmb8), mRNA.
        5.05             2.56               1400041              NM_018734           Gbp2                                        Mus musculus guanylate binding protein 2 (Gbp2), mRNA.
        5.02             4.24               1580528              NM_011909           Usp18                                    Mus musculus ubiquitin specific peptidase 18 (Usp18), mRNA.
        4.89             3.63               7510020              NM_010501           Ifit3                      Mus musculus interferon-induced protein with tetratricopeptide repeats 3 (Ifit3), mRNA.
         4.8             3.08               6760390              NM_010387           H2-D1                                 Mus musculus histocompatibility 2, D region locus 1 (H2-D1), mRNA.
        4.47             4.23               4830010              NM_011854           Oasl2                                 Mus musculus 2′-5′ oligoadenylate synthetase-like 2 (Oasl2), mRNA.
        4.13             2.96                60553               NM_018734           Gbp3                                  Mus musculus guanylate nucleotide binding protein 3 (Gbp3), mRNA.
        3.98             3.67               5270398              NM_008332           Ifit2                      Mus musculus interferon-induced protein with tetratricopeptide repeats 2 (Ifit2), mRNA.
        3.04             1.52               3940639              NM_027450          Glipr2                                      Mus musculus GLI pathogenesis-related 2 (Glipr2), mRNA.
        2.96             1.62               4830543              NM_023065           Ifi27                                 Mus musculus interferon, alpha-inducible protein 27 (Ifi27), mRNA.
        2.93             1.45                430167              NM_008534           Ly86                                           Mus musculus lymphocyte antigen 86 (Ly86), mRNA.
        2.62             1.63               3140209              NM_013655          Cxcl10                                   Mus musculus chemokine (C-X-C motif) ligand 10 (Cxcl10), mRNA.
        2.59             1.67               2230386              NM_008348           Iigp2                                     Mus musculus interferon inducible GTPase 2 (Iigp2), mRNA.
         2.5             1.81                830762              NM_026030          Eif2ak2                     Mus musculus eukaryotic translation initiation factor 2-alpha kinase 2 (Eif2ak2), mRNA.
        2.47             1.94               6660634              NM_008390           Irf1                                      Mus musculus interferon regulatory factor 1 (Irf1), mRNA.
        2.14             1.35               6660176              NM_213659           Stat3                Mus musculus signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA.
        2.08             1.94               2000373              NM_009825         Serping1                    Mus musculus serine (or cysteine) peptidase inhibitor, clade G, member 1 (Serping1), mRNA.
        2.06             1.33               3780736            NM_001001892          H2-K1                        Mus musculus histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA.
        1.93             1.39                130598              NM_011852           Oas1g                                  Mus musculus 2′-5′ oligoadenylate synthetase 1 G (Oas1g), mRNA.
         1.9             1.49               5720255              NM_201394           Pld4                                     Mus musculus phospholipase D family, member 4 (Pld4), mRNA.
        1.86             1.43               4120014              NM_008330           Ifi35                                     Mus musculus interferon-induced protein 35 (Ifi35), mRNA.
        1.85             1.48               4150050              NM_133779           Pigt                    Mus musculus phosphatidylinositol glycan anchor biosynthesis, class T (Pigt), mRNA. XM_922599
        1.84             1.87               3060482              NM_008394           Irf9                                      Mus musculus interferon regulatory factor 9 (Irf9), mRNA.
        1.81             1.29               2100484              NM_025928          Plxnb2                              PREDICTED: Mus musculus plexin B2, transcript variant 13 (Plxnb2), mRNA.
        1.76             1.84                240725              NM_009283           Stat1                           Mus musculus signal transducer and activator of transcription 1 (Stat1), mRNA.
        1.72             2.11                520278              NM_024263            Mx2                                  Mus musculus myxovirus (influenza virus) resistance 2 (Mx2), mRNA.
        1.67              1.4               5870093              NM_011530           Tap1                        Mus musculus transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (Tap1), mRNA.
        1.64             1.37               6770114            NM_001012236          Trem2                            Mus musculus triggering receptor expressed on myeloid cells 2 (Trem2), mRNA.
        1.61             1.29               3780279              NM_026116            Bax                                         Mus musculus Bcl2-associated X protein (Bax), mRNA.
        1.55             1.32               5130139              NM_009369           Tgfb1                                   Mus musculus transforming growth factor, beta 1 (Tgfb1), mRNA.
        1.55             1.22               1090139              NM_008332           Ifi47                                 Mus musculus interferon gamma inducible protein 47 (Ifi47), mRNA.
        1.53              1.3               3060450              NM_011854           Oas2                                     Mus musculus 2′-5′ oligoadenylate synthetase 2 (Oas2), mRNA.
        1.49             1.29               6590653              NM_008320           Irf7                                      Mus musculus interferon regulatory factor 7 (Irf7), mRNA.
        1.47             1.49               5870398              NM_011970          Psmb10                         Mus musculus proteasome (prosome, macropain) subunit, beta type 10 (Psmb10), mRNA.
        1.45             1.25                460435              NM_016660          Hmg20b                                       Mus musculus high mobility group 20 B (Hmg20b), mRNA.
        1.42             1.22                290494              XM_894155         BC004012                                               Mus musculus Nadk NAD kinase, mrNA.
         1.4             1.42               6220594              NM_213659           Stat2                           Mus musculus signal transducer and activator of transcription 2 (Stat2), mRNA.
         1.4             1.37               4810072              NM_008490           Lcat                                   Mus musculus lecithin cholesterol acyltransferase (Lcat), mRNA.
        1.39             1.42               2450554              NM_011175           Lgi4                                 Mus musculus leucine-rich repeat LGI family, member 4 (Lgi4), mRNA.
        1.38             1.24               2480373              NM_026836           Taf10               Mus musculus TAF10 RNA polymerase II, TATA box binding protein (TBP)-associated factor (Taf10), mRNA.
        1.33             1.39               6550376              NM_008529           Ly6e                                   Mus musculus lymphocyte antigen 6 complex, locus E (Ly6e), mRNA.
        1.33             1.21                540411              NM_177663           Isg20                                     Mus musculus interferon-stimulated protein (Isg20), mRNA.
        1.31             1.42               7210687              NM_007471           Apoe                                             Mus musculus apolipoprotein E (Apoe), mRNA.
        1.26             1.22                990129              NM_026960           Grwd1                                 Mus musculus glutamate-rich WD repeat containing 1 (Grwd1), mRNA.
        1.24             1.19               5870255              NM_028162         Tbc1d10a                                  Mus musculus TBC1 domain family, member 10a (Tbc1d10a), mRNA.
        1.22             1.49               4890626              NM_008879           Lcn2                                                Mus musculus lipocalin 2 (Lcn2), mRNA.

![**Expression of interferon signaling genes is upregulated in AblPP/tTA mice, but expression of interferons themselves are not.** Quantitative real-time PCR of AblPP/tTA mouse cortex and hippocampus versus wild-type mouse cortex and hippocampus at 2 and 4 weeks off doxycyline. \**P* \< 0.05, \*\**P* \< 0.01.](1742-2094-9-208-3){#F3}

We confirmed that STAT1, a key signaling molecule in the interferon pathway, is upregulated on a protein level in AblPP/tTA mouse forebrain by immunoblotting. Additionally, STAT1 expression is not only upregulated, but the protein itself is activated by phosphorylation at Y701 and Y727 (Figure [4](#F4){ref-type="fig"}). Phosphorylation of tyrosine 701 on STAT1 activates the protein, and phosphorylation of this site is necessary for STAT1 dimerization and translocation into the nucleus \[[@B31]\]. STAT1 signals remain high and seem to increase at 4 weeks off doxycyline, indicating that the interferon signaling pathway activation in AblPP/tTA mice is most likely not a transient event.

![**Levels of activated STAT1 are increased in AblPP/tTA mice 2 and 4 weeks off doxycycline.** Western blot membranes were probed with antibodies to STAT1 pY701, STAT pS727, STAT1, and β-actin loading control. STAT1 pY701, STAT1 pS727, and STAT1 total protein levels were elevated in AblPP mice expressing constitutively active c-Abl for 2 and 4 weeks compared with wild-type controls.](1742-2094-9-208-4){#F4}

Interferon signaling is upregulated in neurons of the CA1 region of the hippocampus
-----------------------------------------------------------------------------------

In order to determine the cell type that demonstrates an increased expression of STAT 1, immunohistochemistry and double-labeling experiments were performed. In Figure [5](#F5){ref-type="fig"}, we show that STAT1 is elevated in neurons in the CA1 region of the hippocampus in AblPP/tTA mice, and that STAT1 co-localizes with the neuronal marker NeuN. These data indicate that STAT1 expression is induced in neurons themselves. Intriguingly, the STAT1 staining co-localizes to the CA1 region of the hippocampus, which experiences severe neuronal loss in aged AblPP/tTA mice.

![**STAT1 expression occurs in neurons of the CA1 region of the hippocampus in AblPP/tTA mice prior to neuronal loss.**(**A**-**E**) STAT1 immunohistochemistry of the CA1 region of an AblPP/tTA mouse expressing constitutively active c-Abl for 3 weeks (**B**,**D**,**E**) versus wild-type control (A,C). (**F**,**G**) STAT1pY701 immunohistochemistry the CA1 region of a wild-type mouse (**F**) versus an AblPP/tTA mouse 3 weeks off doxycyline (**G**). Cells positive for STAT1 pY701 are indicated with arrows. (**H**,**I**) Double labeling with NeuN (green) and total STAT1 (red) in wild-type (panel H) and AblPP mice expressing constitutively active c-Abl for 2 weeks (panel I). Scalebars: A,B = 2 mm; C,D,F,G = 800 μm; E = 400 μm.](1742-2094-9-208-5){#F5}

Discussion
==========

It has been shown previously that c-Abl activation in adult neurons leads to neurodegeneration and neuroinflammation \[[@B8]\]. However, the mechanism by which c-Abl activation leads to these consequences remains unknown. In the work presented here, we show a correlation between c-Abl activation and the induction of two cell signaling pathways. First, transient but strong expression of cell cycle related proteins and DNA replication occurs in the olfactory bulb. Second, induction of interferon signaling genes occurs in the hippocampus, and the major signaling molecule of this pathway, STAT1, is upregulated in neurons in the CA1 region.

The first pathway examined was the cell cycle. The data show that expression of cell cycle related proteins and DNA replication does occur in AblPP/tTA mice, indicating that the cell cycle is activated, at least partially through S-phase. However, these findings do not localize to the CA1 region of the hippocampus. This suggests that aberrant cell cycle activation does not play a role in neuronal death observed in pyramidal neurons in CA1 of AblPP/tTA mice. Increased BrdU incorporation occurred mainly in the olfactory bulb, although BrdU-labeled cells were also found along a pathway anatomically consistent with the rostral migratory stream (data not shown). There is abundant expression of AblPP in the olfactory bulb \[[@B8]\].

Interestingly, BrdU labeling occurred in cells in the olfactory bulb when BrdU was administered at 2 weeks off doxycyline and mice were euthanized immediately, but BrdU labeling precipitously decreased when mice were administered BrdU at 2 weeks off doxycyline then aged for a further 4 weeks (Figure [2](#F2){ref-type="fig"}). Therefore, the cells that undergo DNA replication in the olfactory bulb of AblPP/tTA mice do not appear to survive for an extended period of time. The number of cells labeled in the dentate gyrus of AblPP/tTA mice also appears to decrease. This raises the possibility that c-Abl strongly induces DNA replication and possibly aberrant cell cycle activation at early time points, but that the cells that undergo this process may have impaired survival and decreased ability to replicate DNA as the mice age. BrdU labeling experiments performed on older AblPP/tTA mice support this hypothesis. In mice that were administered BrdU for 5 days prior to euthanization at 11 weeks off doxycyline, no labeling of the dentate gyrus occurred (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1).

The second pathway that we examined was interferon signaling. Our findings that interferon stimulated genes are induced in the presence of active c-Abl are consistent with previous reports showing that P210 BCR/Abl can induce expression of interferon responsive genes, including OAS1, IFIT1, IFI16, ISGF3G, and STAT1, in U937 cells in culture \[[@B32]\]. Also consistent with other studies, we find no evidence of significant induction of interferons themselves \[[@B32]\]. While other groups have focused on myeloid cells, this is the first evidence that interferon signaling pathways are induced by c-Abl activation in adult neurons *in vivo*. These data suggest that the AblPP/tTA mouse model will be useful to investigate the role of interferon signaling in neurodegeneration and neuroinflammation.

Given that STAT1, the major signaling molecule downstream of the interferons, was activated in the same anatomical region in which neurodegeneration occurs in AblPP/tTA mice, it is possible that STAT1 activation and interferon signaling play a role in c-Abl induced pathology in the CA1 region of the hippocampus. STAT1 activation has been associated with death in terminally differentiated cells and has been shown to play a role in apoptosis in response to TNFα treatment in cell culture \[[@B33]\]. Ischemia-reperfusion induced death is enhanced by STAT1 in cardiac myocytes, which, like neurons, are terminally differentiated \[[@B34],[@B35]\]. Treatment of mice with paraquat, a toxin that induces selective loss of dopaminergic neurons, resulted in increased expression of STAT1 mRNA in the substantia nigra pars compact in a time course corresponding to dopaminergic neuronal loss \[[@B36]\]. Activated (pY701) STAT1 is upregulated in rat brain during focal cerebral ischemia-reperfusion experiments and localizes to the core of lesions, indicating that it may play a role in cell death during ischemia-reperfusion \[[@B37]\].

The role of other interferon signaling genes in neurodegenerative and neuroinflammatory diseases is less clear. Interferon signaling has been associated with cell loss, and, while we observe no significant increases in expression of interferons themselves, it is reasonable to assume that activation of downstream signaling molecules could have a similar effect as treatment with interferons themselves. In SHSY5Y cells, interferon β treatment results in apoptosis, and pretreatment of interferon β treated cells with P6, a pan-JAK inhibitor that results in downstream inhibition of STATs, led to decreased caspase 9, 7, and 3 cleavage and decreases in PARP expression, resulting in rescue of the apoptotic phenotype \[[@B38]\]. In primary neuronal cultures, long-term treatment with interferon β led to loss of neuritic processes and increased pY701 STAT1 and caspase 3 levels \[[@B38]\], and interferon γ knockout mice exhibited less neuronal loss in response to paraquat treatment, suggesting that interferon γ signaling may play a role in paraquat-induced neuronal loss \[[@B36]\]. Interferon regulatory factor 1 is thought to play a role in neuronal death in response to ischemia \[[@B39]\]. However, interferon regulatory factors 3 and 7 have been shown to be necessary for neuroprotection in multiple preconditioning paradigms for ischemia reperfusion injury \[[@B40]\].

While the precise role of cell cycle activation and interferon signaling in response to c-Abl activation in neurons remains unclear, we have demonstrated that c-Abl activation leads to an early, transient induction of cell cycle activation in the olfactory bulb and rostral migratory stream and to induction of interferon stimulated genes without (or prior to) induction of interferon expression. One interpretation of these data is that the cell cycle activation observed may be due to a transient stimulation of neurogenesis, although further studies would be necessary to confirm this hypothesis. Interestingly, there is evidence that interferon signaling downstream of c-Abl may have a role to play in stimulation of neurogenesis, as interferon treatment in 3xTg mice lead to increased neurogenesis in addition to increased severity of amyloid pathology and inflammation \[[@B41]\].

The localization of STAT1 activation in the CA1 region of the hippocampus, where severe neuronal loss and neuroinflammation occurs in aged AblPP/tTA mice, suggests that c-Abl induced expression of interferon signaling genes may play a role in the development of neuroinflammation and neurodegeneration observed in these mice. Further studies are necessary to determine whether STAT1 and other interferon signaling genes play a causative or protective role in neurodegeneration and neuroinflammation in AblPP/tTA mice. However, these data show a correlation between sites of neurodegeneration and gliosis and interferon signaling. Overall, these data show that the AblPP/tTA mouse may be an excellent model of sterile neuroinflammation in the context of neurodegeneration and could be used to elucidate the role of interferon signaling in neuroinflammatory and neurodegenerative disorders.
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###### Additional file 1

**Figure S1.**Neurogenesis is apparently lost in AblPP/tTA mice with age. Bromodeoxyuridine (BrdU) labeling of the dentate gyrus of wild-type versus AblPP/tTA mice at 11 weeks off doxycyline. Scalebars = 400 μm. The localization of BrdU labeled cells is consistent with the distribution of neuroblasts.
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